Zydus Lifesciences Q2FY26 Profit Surges 38% to ₹1,258.6 Crore; Revenue Rises 17%

Ahmedabad, November 6, 2025: Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE | BSE: 532321) reported a strong performance for the quarter ended September 30, 2025, with consolidated net profit rising 38% year-on-year (YoY) to ₹1,258.6 crore, driven by broad-based growth across formulations and wellness businesses. Revenue from operations grew 17% YoY to ₹6,123.2 crore, underscoring the company’s diversified portfolio strength.

Key Financial Highlights

The company generated ₹6,123.2 crore in revenue from operations during the quarter, marking a 16.9% YoY increase from ₹5,237 crore in Q2FY25. However, this represented a 6.9% quarter-on-quarter (QoQ) decline from ₹6,573.7 crore in Q1FY26.

Zydus Lifesciences’ EBITDA stood at ₹2,015.8 crore, a 37.9% YoY increase but a 3.5% QoQ decrease. The EBITDA margin improved both YoY and QoQ, reaching 32.9%. Continuing this trend, profit before tax (PBT) came in at ₹1,687.4 crore, up 32.8% YoY, while profit after tax (PAT) was ₹1,258.6 crore, a 38.1% YoY rise.

For the first half of FY26, the company sustained its growth momentum, recording revenue from operations of ₹12,696.9 crore, an increase of 11% year-on-year. The EBITDA stood at ₹4,104.3 crore, up 16% YoY, with a healthy margin of 32.3%, reflecting an improvement of 130 basis points compared to the previous year. Profit before tax (PBT) rose 14% to ₹3,608 crore, while net profit grew 17% year-on-year to ₹2,725.4 crore. The company incurred an organic capex of ₹893 crore during H1FY26.

Zydus maintained a strong financial position, with a net debt-to-equity ratio of 0.09x and a net debt-to-EBITDA ratio of 0.3x, underscoring its robust financial discipline and healthy balance sheet.

R&D and Pipeline Progress

The company invested 7.9% of the quarter’s revenue in research and development, totalling ₹482 crore. It reported positive Phase 2(b)/3 results for Saroglitazar Magnesium in the treatment of Primary Biliary Cholangitis (PBC) and plans to file a New Drug Application (NDA) with the USFDA in Q4 FY26. Additionally, Zydus received clearance to begin Phase II trials for its Bivalent Typhoid Conjugate Vaccine in India, strengthening its vaccine portfolio.

Operational and Regulatory Updates

Zydus recently received Establishment Inspection Reports (EIRs) with Voluntary Action Indicated (VAI) status for its oncology injectable facility in Ahmedabad and the Baddi formulations plant. The company also received NAI status for its SEZ II facility following a pre-approval inspection — reflecting its ongoing compliance with stringent global manufacturing standards.

Market Snapshot

The share price of Zydus Lifesciences Limited closed at ₹934.80 on November 06, 2025. This is a 3.80% or ₹36.90 decrease from its previous close of ₹971.70. The intraday range was between ₹933.05 and ₹998.00. The company has had a decent trading session. Its total market capitalisation stood at ₹94,062.75 crore. Further, it had a total traded value and volume of ₹280.25 crore and 29.20 lakh shares, respectively.

REF: https://nsearchives.nseindia.com/corporate/Cadilahc_06112025130923_PressRelease.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations